Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
The TENDERS study aims to evaluate the impact of the timing of renal replacement therapy (RRT) initiation on outcomes in patients with tumor lysis syndrome (TLS) and associated acute kidney injury (AKI). The study will compare early versus delayed RRT initiation, examining the effect on renal function at 30 days post-treatment.
Eligibility criteria
Qualifiers
Adults aged ≥18 years.
Hospitalized in the ICU between January 1, 2013, and December 31, 2023.
Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy.
Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation.
Disqualifiers
Patient or family opposition to data collection for research purposes.
Incomplete medical records that preclude data extraction.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
800 Participants
are grouped into 2 trial groupsLocations
10CHU d'Angers Angers France
Hôpital Pellegrin Bordeaux France
Hôpital la cavale blanche Brest France
CHU Dupuytren 1 Limoges France
Sponsors and collaborators
University Hospital, Bordeaux
Lead sponsor
Source ClinicalTrials.gov